|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Jan.08 -- McKesson Corp. CEO John Hammergren speaks with Bloomberg’s Erik Schatzker at the JPMorgan Healthcare Conference about tech giants’ role in pharmaceuticals.
Jan.08 -- McKesson Corp. Chief Executive Officer John Hammergren speaks with Bloomberg’s Erik Schatzker at the JPMorgan Healthcare Conference and refutes criticism that his drug distribution company did not do enough to prevent the opioid epidemic.
Jan.08 -- McKesson Corp. chief executive officer John Hammergren speaks with Bloomberg’s Erik Schatzker at the JPMorgan Healthcare Conference and forcefully refutes criticism that his drug distribution company did not do enough to prevent the opioid epidemic. They also discuss technology giants' role in pharmaceuticals.
New York City is following a wave of lawsuits against opioid manufacturers and distributors in accusing the companies of oversupplying the market and misrepresenting the safety of the drugs.
In case you missed it, here are some of Benzinga's top stories from Tuesday, Jan. 23, 2018. Talkin’ Tariffs In exclusive comments to Benzinga, see how the Whirlpool Corporation (NYSE: WHR ) Chairman, along ...
New York City said on Tuesday it has sued several companies that make or distribute prescription opioids, seeking to hold them accountable for their role in what it called a deadly epidemic afflicting ...
Kentucky's attorney general on Monday accused drug distributor McKesson Corp of helping fuel the opioid epidemic by failing to halt shipments of suspiciously large or frequent orders by pharmacies of prescription painkillers. The complaint by Kentucky Attorney General Andy Beshear was filed in a state court and was one of a flurry of lawsuits by states and local governments against opioid manufacturers and distributors seeking to hold them accountable for the U.S. epidemic. McKesson did not immediately respond to a request for comment.
McKesson (MCK) continues to pursue deals, divestitures and acquisitions to drive growth. The company's impressive performance in 2017 accounts for its potential to sustain the momentum.
It could be weeks or a year before the deals that biotech executives and financiers started at last week's 36th J.P. Morgan Healthcare Conference come to fruition. McKesson Corp. (MCK), the San Francisco-based health care products distribution company, has been a target of those looking to find a source of the nation's epidemic of pain-killing opioid drugs.
A Relative Strength Rating upgrade for Allscripts Healthcare Solutions shows improving technical performance.
In the Bloomberg video above , McKesson Corp. Chief Executive Officer John Hammergren refutes criticism that his drug distribution company did not do enough to prevent the opioid epidemic. Hammergren speaks with Bloomberg’s Erik Schatzker at the JPMorgan Healthcare Conference. The Washington Post and CBS' "60 Minutes" last month jointly reported on an investigation of McKesson led by the U.S. Drug Enforcement Administration's Denver team that looked into the pharmaceutical giant's distribution of powerful opioid prescription drugs in Colorado and elsewhere.
COLUMBUS, Ohio (AP) — A federal judge on Tuesday set a goal of doing something about the nation's opioid epidemic this year, while noting the drug crisis is "100 percent man-made."
In the past few weeks, McKesson has been unhappily tied to stories about opioids, including coverage on TheStreet. At the JPMorgan Healthcare Conference, the company took its case to investors.
McKesson Technologies LLC in Alpharetta has been awarded a $400 million federal contract to supply and maintain digital imaging network picture archiving and communication system products and maintenance. Change Healthcare and McKesson Technology Solutions, a division of McKesson Corp. (MCK), combined in March 2017 , and the McKesson Imaging business became a part of the new Change Healthcare, a Change Healthcare spokeswoman said. The contract has a five-year base with one five-year option period, according to the Department of Defense.
The crisis could seemingly turn a number of companies on their heads much in the way that big tobacco suits of the late 1990s forever changed the tobacco industry.
McKesson (MCK) has been actively pursuing deals, divestitures and acquisitions to drive growth. The latest buyout will boost Specialty Health business.